A total of 388 case reports of primary suspect IL-17 inhibitor-related gastrointestinal inflammatory conditions were identified in the FAERS database, which included 268 IBD diagnoses and 120 colitis diagnoses. Here, IL17A is linked to inflammatory bowel disease.